Genfit (GNFT) AI Stock Analysis

Compare

9 Followers

Top Page

Genfit

(OTC:GNFT)

Rating:62Neutral

Price Target:―

Genfit's overall stock score reflects its strong financial recovery and technical momentum, tempered by concerns about historical revenue volatility and asset reduction. The high P/E ratio suggests potential overvaluation, which, along with overbought technical indicators, warrants caution. While the financial health is stable, future performance will depend significantly on maintaining revenue growth and asset sustainability.

Genfit (GNFT) vs. iShares MSCI France ETF (EWQ)

Market Cap

€185.69M

Dividend YieldN/A

Average Volume (3M)261.41K

Price to Earnings (P/E)118.2

Beta (1Y)1.30

Revenue Growth134.56%

EPS GrowthN/A

CountryFR

Employees180

SectorHealthcare

Sector Strength42

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.56

Shares Outstanding49,996,185

10 Day Avg. Volume159,805

30 Day Avg. Volume261,413

Financial Highlights & Ratios

PEG Ratio-1.38

Price to Book (P/B)2.86

Price to Sales (P/S)0.00

P/FCF Ratio13.46

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€8.70

Price Target Upside133.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Genfit Business Overview & Revenue Model

Company DescriptionGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

How the Company Makes MoneyGenfit makes money primarily through the development and commercialization of its therapeutic and diagnostic products. Revenue streams include licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of approved drugs and diagnostics. Significant partnerships with companies and research institutions help advance its pipeline and share costs and profits from successful product commercialization. Additionally, Genfit may receive milestone payments and royalties based on the development and commercialization stages of its partnered products. The company also invests in research and development to continually innovate and expand its product offerings, which can lead to future revenue growth.

Genfit Financial Statement Overview

Summary

Genfit has shown significant improvement in financial performance in 2024, with a return to profitability and stronger cash flows. Effective cost management and operational efficiency are evident, but concerns remain about historical revenue volatility and asset reduction. The financial health is stable with a balanced debt-to-equity ratio, though long-term asset sustainability and profitability need close monitoring.

Income Statement

Positive

Genfit experienced a significant recovery in 2024 with a substantial increase in revenue from 2023, resulting in a return to profitability with a net profit margin of 2.25%. The gross profit margin is robust at 99.55%, indicating effective cost management. EBIT and EBITDA margins have improved significantly, reflecting enhanced operational efficiency. However, the revenue growth has been volatile over the years, indicating a lack of stability in sales performance.

Balance Sheet

Neutral

The company's financial structure shows a moderate debt-to-equity ratio of 0.90, indicating a balanced use of debt and equity. Return on Equity (ROE) is modest at 2.18%, suggesting limited profitability for shareholders. The equity ratio of 45.73% indicates a healthy balance sheet with adequate equity cushion. However, the substantial decrease in total assets over recent years might pose a risk to long-term asset sustainability.

Cash Flow

Positive

Genfit's cash flow position has improved, with a strong free cash flow growth from the previous year and a solid free cash flow to net income ratio of 9.44. The operating cash flow to net income ratio of 10.09 demonstrates effective cash generation from operations. However, the past volatility in operating cash flows might indicate future cash flow uncertainties.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
67.00M	28.57M	20.20M	80.07M	765.00K
	Gross Profit
66.70M	28.22M	19.95M	79.91M	563.00K
	EBIT
3.28M	-26.58M	-27.55M	76.74M	-77.79M
	EBITDA
8.35M	-22.24M	-23.60M	34.91M	-91.14M
	Net Income Common Stockholders
1.51M	-28.89M	-23.72M	67.26M	-101.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
81.79M	77.79M	140.55M	258.76M	171.03M
	Total Assets
151.42M	173.87M	215.54M	281.72M	198.61M
	Total Debt
62.13M	70.18M	75.28M	74.23M	185.69M
	Net Debt
-19.66M	-7.61M	-60.73M	-184.52M	14.66M
	Total Liabilities
82.20M	105.92M	121.01M	162.62M	214.78M
	Stockholders Equity
69.22M	67.95M	94.53M	119.10M	-16.16M
Cash Flow		Free Cash Flow
14.22M	-57.92M	-72.64M	99.38M	-97.27M
	Operating Cash Flow
15.20M	-55.43M	-72.64M	99.92M	-96.37M
	Investing Cash Flow
-1.04M	2.23M	-46.27M	-3.38M	-966.00K
	Financing Cash Flow
-10.22M	-5.10M	-3.79M	-8.92M	-8.26M

Genfit Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price3.72

Price Trends

50DMA

3.56

Positive

100DMA

3.54

Positive

200DMA

3.92

Negative

Market Momentum

MACD

0.07

Positive

RSI

46.41

Neutral

STOCH

20.32

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GNFT, the sentiment is Neutral. The current price of 3.72 is below the 20-day moving average (MA) of 3.87, above the 50-day MA of 3.56, and below the 200-day MA of 3.92, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 46.41 is Neutral, neither overbought nor oversold. The STOCH value of 20.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:GNFT.

Genfit Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNFT	62 Neutral	€185.69M	118.16	2.17%	―	134.56%	―
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
IPHYF		$201.37M	―	-160.99%	―	―	―
0RA9		€466.82M	―	-148.98%	―	―	―
0QAJ		€202.04M	―	-199.50%	―	―	―
0QAV		€195.78M	―		―	―	―
6OP		€135.02M	3.58	86.78%	―	―	―

* Healthcare Sector Average

Performance Comparison

FR:GNFT

Genfit

3.72

-1.18

-24.04%

IPHYF

Innate Pharma SA

1.45

-1.17

-44.66%

GB:0RA9

Abivax SA

7.48

-5.48

-42.28%

GB:0QAJ

DBV Technologies

1.49

0.49

49.00%

GB:0QAV

Nanobiotix

4.14

-1.01

-19.61%

DE:6OP

OSE Immunotherapeutics SA

6.18

-1.54

-19.95%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.